Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual-target CAR-T therapies which...
Saved in:
Main Authors: | Chenyun Zhang, Haizhou Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/jimr/5845167 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01) -
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
by: Haiying Qin, et al.
Published: (2021-09-01) -
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
by: Marie José Kersten, et al.
Published: (2025-01-01) -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01) -
The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy
by: Jinlan Long, et al.
Published: (2025-01-01)